AVAIL is excited to announce a major milestone in its journey of advancing life sciences innovation: the successful raise of $75,000,000 in funding. This significant investment reinforces AVAIL Global Network’s standing as a leader in driving viable, applicable innovations through its unique combination of robust research and strategic consulting. The network, composed of top-tier organizations committed to R&D and consulting, is well-positioned to accelerate breakthroughs in life sciences. At the heart of this initiative is the Avail Biomedical Research Institute—a discovery and preclinical research institution with GMP- and GLP-compliant facilities that drive in-house explorations and support collaborative investigations. The institute excels in diverse areas such as optimizing and testing pulmonary disease models, conducting cell characterization and secretome analyses, spearheading in-vitro tissue engineering, and executing comprehensive pharmacokinetic and pharmacodynamic drug testing. Moreover, its capabilities extend to exploratory toxicology, biomarker discovery with fit-for-purpose validation, and conducting drug/biomarker pairing and validation studies.
Parallel to these efforts, Avail Pharma provides strategic R&D consulting that propels lead projects from the research phase to market readiness by translating scientific breakthroughs into innovative and commercially viable products. The recent funding will empower AVAIL to further enhance its state-of-the-art facilities, expand its research capabilities, and accelerate efforts in all key focus areas. By leveraging these resources, the company is poised to make transformative contributions to patient care, ensuring that promising research not only reaches the bench but also makes a tangible impact in the clinical arena. This infusion of capital marks a new phase of growth and innovation, reaffirming AVAIL’s commitment to revolutionizing life sciences research and development for the benefit of patients worldwide.
